Which of these Footsie healthcare stars should you buy after today’s news?

Royston Wild discusses the investment prospects of two Footsie medical giants.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

News of declining earnings has seen private hospital group Mediclinic International (LSE: MDC) fail to keep touch with its FTSE 100 peers in Thursday business, the stock last seen dealing 6% lower on the day.

Mediclinic — which operates medical facilities across South Africa, Switzerland and the United Arab Emirates — announced that underlying earnings per share dropped 26% during April-September, due to the cost of acquiring the Al Noor hospital group.

This is not the first time Mediclinic’s Middle Eastern operations have spooked investors. Indeed, several factors — changes to medical insurance cover in the region, a large number of doctor vacancies, and delayed facility openings, such as that of the Al Jowhara hospital — forced the company to scale back its revenues guidance in September.

Despite these problems, I believe that Mediclinic remains an attractive pick for long-term investors. Indeed, the healthcare giant saw revenues gallop 27% higher during the fiscal first half, to £1.28bn, with Al Noor contributing 16% to this sales growth.

These figures underline the growing need for private healthcare in emerging regions, a phenomenon that looks set to continue as disposable income levels grow. And Mediclinic is also performing extremely well in its traditional markets, too, and enjoyed a solid 5% revenues upswing in Switzerland during the half year.

The City certainly expects sales at Mediclinic to keep charging higher, resulting in earnings growth of 17% and 19% in the years to March 2017 and 2018 respectively.

Consequent P/E ratings of 20.1 times and 16.9 times may be slightly expensive from a ‘classic’ investing perspective — these readings are ahead of the Footsie forward average of 15 times. However, I believe Mediclinic’s white-hot growth prospects warrant this slight premium.

The right medicine?

Medicine maker Hikma Pharmaceuticals (LSE: HIK) has also endured fresh share price losses today, the stock last 3% lower from Wednesday’s session.

Disappointing volume growth at its Generics unit has forced Hikma to announce a downward revision to its 2016 revenues target, the company now expecting full-year sales at the division to clock in at $600m versus its previous target of between $640 and $670m. Consequently Hikma now expects group revenues to come in at between $2bn and $2.1bn, down from its prior guidance of $2bn.

Still, Hikma remains bullish on the long-term prospects of its Generics operations, and expects sales here to shoot to $800m in fiscal 2017 on the back of “market share gains of high value products, portfolio rationalisation and pipeline execution.”

Of course investment in the pharma sector is always fraught with risk — such is the nature of drugs development. But I believe the strength of Hikma’s bubbly product pipeline, not to mention benefits resulting from recent acquisition activity, make it a potentially-explosive growth selection.

The City certainly expects Hikma to recover from its current troubles, and rebound from a 24% earnings decline in 2016 to print a 35% rise next year. With the P/E rating expected to consequently topple from 19.5 times for this year to 14.4 times, I reckon the drugs giant is worthy of serious attention.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Should I follow Warren Buffett and sell my favourite shares?

Billionaire US investor Warren Buffett has been selling tons of Apple shares and other stocks of businesses he thinks are…

Read more »

Investing Articles

As like-for-like sales continue to fall, is the B&M European Value Retail SA (LSE:BME) share price a bargain?

B&M European Value Retail is known for its low prices, but could growing like-for-like sales make the share price the…

Read more »

Illustration of flames over a black background
Investing Articles

After rocketing 232% in a year can this red-hot FTSE 250 stock keep going gangbusters?

Harvey Jones says this FTSE 250 stock's on fire after smashing the index over the last year. It's cheaper than…

Read more »

Investing Articles

The Burberry share price has jumped 15% this morning! Time to pile in?

Harvey Jones was thrilled to wake up this morning and find the Burberry share price flying, but he's still sitting…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

At a bargain-basement price now, is it time for me to buy this 8%-yielding FTSE 250 media stock?

Shares in this FTSE 250 broadcasting firm continued their recent decline after the latest results release, leaving them looking an…

Read more »

Investing For Beginners

Here’s what a landmark legal ruling could mean for the Lloyds share price

Jon Smith mulls over whether issues with historical motor finance commissions could spell trouble for the Lloyds share price into…

Read more »

Investing Articles

I’d buy 4,186 Legal & General shares to aim for £14,616 a year in passive income

A relatively small sum invested in Legal & General shares can be transformed into much bigger passive income over time…

Read more »